Skip to main content
SpringerLink
Log in

Umgang mit NSAR bei der Behandlung der axialen Spondyloarthritis

Dealing with NSAID in the treatment of axial spondylarthritis

  • So behandle ich ...
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19–34

    Article  PubMed  Google Scholar 

  2. Poddubnyy D, Listing J, Brief Report SJ (2016) Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with Infliximab plus Naproxen as compared to Naproxen alone: results from the Infliximab as first line therapy in patients with early active axial Spondyloarthritis trial. Arthritis Rheumatol 68(8):1899–1903

    Article  CAS  PubMed  Google Scholar 

  3. Poddubnyy D, Sieper J (2017) Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep 19(9):55

    Article  PubMed  Google Scholar 

  4. Haibel H, Redeker I, Zink A, Callhoff J, Marschall U, Hoffmann F et al (2019) Health care and disease burden in persons with axial spondyloarthritis in Germany. Z Rheumatol 78(9):865–874

    Article  CAS  PubMed  Google Scholar 

  5. Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925

    Article  PubMed  Google Scholar 

  6. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163(6):409–416

    Article  PubMed  Google Scholar 

  7. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70(2):249–251

    Article  CAS  PubMed  Google Scholar 

  8. Kroon FP, van der Burg LR, Ramiro S, Landewe RB, Buchbinder R, Falzon L, van der Heijde D (2015) Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010952.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wang R, Dasgupta A, Ward MM (2015) Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2015-207677

    Article  PubMed  Google Scholar 

  10. Fan M, Liu J, Zhao B, Wu X, Li X, Gu J (2020) Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med 19(4):3031–3041

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P et al (2016) A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord 17(1):426

    Article  PubMed  PubMed Central  Google Scholar 

  12. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik m.S. Gastroenterologie, Infektiologie und Rheumatologie, Charité – Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland

    Denis Poddubnyy

  2. Deutsches Rheumaforschungszentrum Berlin, Berlin, Deutschland

    Denis Poddubnyy

Authors
  1. Denis Poddubnyy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis Poddubnyy.

Ethics declarations

Interessenkonflikt

D. Poddubnyy gibt folgende potenzielle Interessenkonflikte an: Forschungsförderung durch: AbbVie, Eli Lilly, MSD, Novartis, Pfizer; Beratertätigkeit für: AbbVie, Bristol-Myers Squibb, Biocad, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB; Referententätigkeit für: AbbVie, Canon, DKSH, Eli Lilly, Janssen, MSD, Medscape, Novartis, PeerVoice, Pfizer und UCB.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Julia Holle, Neumünster

Frank Moosig, Neumünster

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poddubnyy, D. Umgang mit NSAR bei der Behandlung der axialen Spondyloarthritis. Z Rheumatol 82, 882–884 (2023). https://doi.org/10.1007/s00393-023-01449-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-023-01449-9

Search

Navigation